Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Aclaris Therapeutics ( (ACRS) ) has shared an update.
On October 14, 2025, Aclaris Therapeutics will hold an R&D Day to showcase their innovative therapeutic developments. The company is advancing several promising product candidates, including bosakitug, ATI-052, and ATI-2138, which have the potential to be best-in-class treatments for various immune-mediated diseases. Aclaris is well-financed with a cash runway extending into 2028, and they are poised for significant growth with multiple clinical programs and strategic partnerships on the horizon.
The most recent analyst rating on (ACRS) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Aclaris Therapeutics stock, see the ACRS Stock Forecast page.
Spark’s Take on ACRS Stock
According to Spark, TipRanks’ AI Analyst, ACRS is a Neutral.
Aclaris Therapeutics’ overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues and negative profitability. The technical analysis provides some support with positive short-term trends, but the valuation remains unattractive due to the negative P/E ratio and lack of dividend yield. The absence of earnings call data and corporate events means these factors do not influence the score.
To see Spark’s full report on ACRS stock, click here.
More about Aclaris Therapeutics
Aclaris Therapeutics is a company focused on developing therapeutic franchises to address gaps in important immuno-inflammatory (I&I) diseases. They are engaged in patient-focused innovation with a strong emphasis on developing industry-leading inhibitors targeting validated immune targets. Aclaris is positioned in the oral and antibody space, with a robust pipeline of clinical programs and a strategic focus on bispecific and ITK oral programs that could potentially transform multiple indications.
Average Trading Volume: 1,067,832
Technical Sentiment Signal: Hold
Current Market Cap: $202.6M
For a thorough assessment of ACRS stock, go to TipRanks’ Stock Analysis page.